Brief: Maat Pharma Says Maat033 Shows Favorable Safety Profile And Tolerability
07/10/2025 07:42
Oct 7 (Reuters) - Maat Pharma SA MAAT.PA: MAAT PHARMA ANNOUNCES POSITIVE SECOND SAFETY INTERIM ANALYSIS FROM DSMB FOR PHASE 2B PHOEBUS TRIAL EVALUATING MAAT033 FOR PATIENTS RECEIVING ALLO-HSCT MAAT PHARMA SA - MAAT033 SHOWS FAVORABLE SAFETY PROFILE AND TOLERABILITY ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Maat Pharma SA
See all newsBrief: MaaT Pharma Says FDA Indicates No Additional Nonclinical Studies Required For MaaT034 Safety
France's MaaT Pharma H1 operating loss widens on higher R&D costs
Brief: MaaT Pharma SA Receives 'Negative Trend' Opinion For Upcoming June CHMP Vote For MaaT013 (Xervyteg)
France's MaaT Pharma 2025 revenue rises 40.7% but misses expectations
Brief: MaaT Pharma Says Xervyteg Under EMA Review, Decision Expected In H2 2026